摘要
目的:比较利妥昔单抗(商品名:美罗华)联合CHOP(环磷酰胺,阿霉素,长春新碱和泼尼松)与单用CHOP方案化疗治疗弥漫大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)的临床疗效。方法:根据患者的意愿,49例DLBCL患者分别接受6疗程CHOP方案或CHOP加利妥昔单抗方案化疗,每3周1疗程,共6个疗程。结果:R-CHOP组的CR率高于CHOP组,但差异无统计学意义(82.6%VS 65.4%,P=0.173)。中位随访时间为35月(4-66月),R-CHOP组及CHOP组的3年OS分别为75.0%±19.6%,54.9%±20.4%,P=0.043;而3年EFS分别为69.7%±20.9%,45.8%±20.6%,P=0.029。R-CHOP组的3年OS及EFS优于CHOP组,差异有统计学意义。两组患者的不良反应无明显差别。结论:与单用CHOP方案相比,利妥昔单抗联合CHOP方案明显提高DLBCL患者的EFS及OS,而不良反应无明显增加。
Objective:To compare the clinical outcome of cyclophosphamide,doxorubicin,vincristine,and prednisone(CHOP) to rituximab plus CHOP(R-CHOP) in adult patients with diffuse large-B-cell lymphoma.Methods: Previously untreated patients with diffuse large-B-cell lymphoma were assigned according to the Patients' intention to receive either six cycles of CHOP every three weeks or six cycles of CHOP plus rituximab chemotherapy regimen.Results: The rate of complete response was higher in the group that received CHOP plus rituximab than in the group that received CHOP alone(82.6% VS 65.4%,P=0.173),but no statistical difference was found between the groups.With a median follow-up of 35 months,the 3-year overall survival rate and disease-free rate were significantly higher in the CHOP-plus-rituximab group(P=0.043 and P=0.029,respectively).Clinically relevant toxicity was not significantly greater in group of CHOP plus rituximab.Conclusion: The combination of rituximab to the CHOP regimen significantly prolongs disease-free and overall survival in adult patients with diffuse large-B-cell lymphoma,without a clinically significant increase in toxicity.
出处
《现代肿瘤医学》
CAS
2011年第10期2069-2071,共3页
Journal of Modern Oncology